AIM ImmunoTech (NYSE:AIM) Price Target Cut to $5.00 by Analysts at Ascendiant Capital Markets

AIM ImmunoTech (NYSE:AIM) had its target price lowered by Ascendiant Capital Markets from $5.25 to $5.00 in a report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.

AIM ImmunoTech Stock Performance

NYSE:AIM opened at $0.34 on Tuesday. The stock has a market cap of $19.47 million, a price-to-earnings ratio of -0.53 and a beta of -0.35. The business’s 50-day simple moving average is $0.35 and its 200 day simple moving average is $0.39. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.17 and a current ratio of 1.17. AIM ImmunoTech has a one year low of $0.25 and a one year high of $0.68.

AIM ImmunoTech (NYSE:AIM) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million for the quarter. AIM ImmunoTech had a negative return on equity of 269.04% and a negative net margin of 13,952.74%.

Institutional Trading of AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC bought a new position in AIM ImmunoTech Inc. (NYSE:AIM) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech as of its most recent SEC filing. Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).